BACKGROUND: Safe and effective therapeutic management of refractory coronary artery disease (CAD) in heart patients is critical to enhance cardiovascular function and improve quality of life. Current therapies for refractory CAD are inadequate in ameliorating angina and promoting revascularization of ischemic myocardium. HYPOTHESIS: Cardiac shock wave therapy (CSWT) is a safe and effective noninvasive intervention in the management of patients with refractory CAD. METHODS: The study enrolled 9 male patients age 50 to 70 years (5.11 ± 5.46 years) with a diagnosis of CAD and stent implantation (3.00 ± 2.24 stents). CSWT was carried out for 3 months at 3 intervals during the first week of each month (first, third, and fifth day), for a total of 9 therapies per patient. Dobutamine stress echocardiography and radionuclide angiography identified the myocardial ischemic segments. The effects of CSWT on myocardial perfusion and systolic function were examined. Other outcome measures included myocardial injury enzyme markers, angina scale, nitroglycerin dosage, and cardiopulmonary fitness assessments. RESULTS: Improved myocardial blood flow and regional systolic function (stress peak systolic strain rate - 1.10 to - 1.60 s(-1), P = 0.002) were detected in patients following CSWT. Reductions in creatine kinase (87.89 ± 36.69 to 86.22 ± 35.96 IU/L, P = 0.046), creatine kinase MB (10.89 ± 5.73 to 10.11 ± 5.93 IU/L, P = 0.008), aspartate transaminase (interquartile range [IQR], 28.00 to 27.00 IU/L, P = 0.034) were also found. Angina (Canadian Cardiovascular Society scale IQR 3.0 to 2.0, P = 0.035) and nitroglycerin dose reduction (IQR 3.0 to 1.0 times/wk, P = 0.038) were reported. CONCLUSIONS: This study is a preliminary assessment of CSWT in patients with refractory CAD. We report that CSWT is a noninvasive, effective, and safe intervention in the treatment of refractory CAD.
BACKGROUND: Safe and effective therapeutic management of refractory coronary artery disease (CAD) in heartpatients is critical to enhance cardiovascular function and improve quality of life. Current therapies for refractory CAD are inadequate in ameliorating angina and promoting revascularization of ischemic myocardium. HYPOTHESIS: Cardiac shock wave therapy (CSWT) is a safe and effective noninvasive intervention in the management of patients with refractory CAD. METHODS: The study enrolled 9 male patients age 50 to 70 years (5.11 ± 5.46 years) with a diagnosis of CAD and stent implantation (3.00 ± 2.24 stents). CSWT was carried out for 3 months at 3 intervals during the first week of each month (first, third, and fifth day), for a total of 9 therapies per patient. Dobutamine stress echocardiography and radionuclide angiography identified the myocardial ischemic segments. The effects of CSWT on myocardial perfusion and systolic function were examined. Other outcome measures included myocardial injury enzyme markers, angina scale, nitroglycerin dosage, and cardiopulmonary fitness assessments. RESULTS: Improved myocardial blood flow and regional systolic function (stress peak systolic strain rate - 1.10 to - 1.60 s(-1), P = 0.002) were detected in patients following CSWT. Reductions in creatine kinase (87.89 ± 36.69 to 86.22 ± 35.96 IU/L, P = 0.046), creatine kinase MB (10.89 ± 5.73 to 10.11 ± 5.93 IU/L, P = 0.008), aspartate transaminase (interquartile range [IQR], 28.00 to 27.00 IU/L, P = 0.034) were also found. Angina (Canadian Cardiovascular Society scale IQR 3.0 to 2.0, P = 0.035) and nitroglycerin dose reduction (IQR 3.0 to 1.0 times/wk, P = 0.038) were reported. CONCLUSIONS: This study is a preliminary assessment of CSWT in patients with refractory CAD. We report that CSWT is a noninvasive, effective, and safe intervention in the treatment of refractory CAD.
Authors: Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani Journal: J Nucl Cardiol Date: 2002 Mar-Apr Impact factor: 5.952
Authors: Francis J Klocke; Michael G Baird; Beverly H Lorell; Timothy M Bateman; Joseph V Messer; Daniel S Berman; Patrick T O'Gara; Blase A Carabello; Richard O Russell; Manuel D Cerqueira; Martin G St John Sutton; Anthony N DeMaria; James E Udelson; J Ward Kennedy; Mario S Verani; Kim Allan Williams; Elliott M Antman; Sidney C Smith; Joseph S Alpert; Gabriel Gregoratos; Jeffrey L Anderson; Loren F Hiratzka; David P Faxon; Sharon Ann Hunt; Valentin Fuster; Alice K Jacobs; Raymond J Gibbons; Richard O Russell Journal: J Am Coll Cardiol Date: 2003-10-01 Impact factor: 24.094
Authors: Ahmed A Khattab; Broder Brodersen; Daniela Schuermann-Kuchenbrandt; Hans Beurich; Ralph Tölg; Volker Geist; Torsten Schäfer; Gert Richardt Journal: Int J Cardiol Date: 2006-11-09 Impact factor: 4.164
Authors: Anna R Ciampa; Alessandra Carcereri de Prati; Ernesto Amelio; Elisabetta Cavalieri; Tiziana Persichini; Marco Colasanti; Giovanni Musci; Ernst Marlinghaus; Hisanori Suzuki; Sofia Mariotto Journal: FEBS Lett Date: 2005-11-28 Impact factor: 4.124
Authors: Xin Zhang; James D Krier; Carolina Amador Carrascal; James F Greenleaf; Behzad Ebrahimi; Ahmad F Hedayat; Stephen C Textor; Amir Lerman; Lilach O Lerman Journal: J Am Soc Nephrol Date: 2016-06-13 Impact factor: 10.121
Authors: Megha Prasad; Wan Azman Wan Ahmad; Renan Sukmawan; Edward-Bengie L Magsombol; Andrew Cassar; Yuri Vinshtok; Muhammad Dzafir Ismail; Ahmad Syadi Mahmood Zuhdi; Sue Ann Locnen; Rodney Jimenez; Homobono Callleja; Amir Lerman Journal: Coron Artery Dis Date: 2015-05 Impact factor: 1.439
Authors: Hong-Yan Cai; Lin Li; Tao Guo; Y U Wang; Tie-Kun Ma; Jian-Ming Xiao; Ling Zhao; Yin Fang; Ping Yang; H U Zhao Journal: Exp Ther Med Date: 2015-10-20 Impact factor: 2.447
Authors: Johannes Holfeld; Can Tepeköylü; Radoslaw Kozaryn; Anja Urbschat; Kai Zacharowski; Michael Grimm; Patrick Paulus Journal: Inflammation Date: 2014-02 Impact factor: 4.092